These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 23011357

  • 1. The effect of methotrexate on improving serological abnormalities of patients with systemic lupus erythematosus.
    Miyawaki S, Nishiyama S, Aita T, Yoshinaga Y.
    Mod Rheumatol; 2013 Jul; 23(4):659-66. PubMed ID: 23011357
    [Abstract] [Full Text] [Related]

  • 2. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease).
    Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M.
    Ann Rheum Dis; 1997 Jun; 56(6):382-5. PubMed ID: 9227169
    [Abstract] [Full Text] [Related]

  • 3. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 4. Preliminary study of a traditional Chinese medicine formula in systemic lupus erythematosus patients to taper steroid dose and prevent disease flare-up.
    Liao YN, Liu CS, Tsai TR, Hung YC, Chang SJ, Lin HL, Chen YC, Lai HM, Yu SF, Chen CJ.
    Kaohsiung J Med Sci; 2011 Jul; 27(7):251-7. PubMed ID: 21757141
    [Abstract] [Full Text] [Related]

  • 5. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus.
    Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S.
    Arthritis Rheum; 2010 Aug; 62(8):2467-75. PubMed ID: 20506343
    [Abstract] [Full Text] [Related]

  • 6. Clinical disease activity and titers of anti-dsDNA antibodies measured by an automated immunofluorescence assay in patients with systemic lupus erythematosus.
    López-Hoyos M, Cabeza R, Martínez-Taboada VM, Crespo J, SanSegundo D, Blanco R, López-Escribano H, Peña M, Rodríguez-Valverde V.
    Lupus; 2005 Aug; 14(7):505-9. PubMed ID: 16130504
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2018 Aug; 70(8):1256-1264. PubMed ID: 29671280
    [Abstract] [Full Text] [Related]

  • 8. Hyperprolactinemia in males with systemic lupus erythematosus.
    Mok CC, Lau CS, Lee KW, Wong RW.
    J Rheumatol; 1998 Dec; 25(12):2357-63. PubMed ID: 9858430
    [Abstract] [Full Text] [Related]

  • 9. Serum ferritin level correlates with SLEDAI scores and renal involvement in SLE.
    Tripathy R, Panda AK, Das BK.
    Lupus; 2015 Jan; 24(1):82-9. PubMed ID: 25253568
    [Abstract] [Full Text] [Related]

  • 10. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.
    ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG.
    Arthritis Rheum; 1990 May; 33(5):634-43. PubMed ID: 2346519
    [Abstract] [Full Text] [Related]

  • 11. CD69 to CD3 ratio of peripheral blood mononuclear cells as a marker to monitor systemic lupus erythematosus disease activity.
    Su CC, Shau WY, Wang CR, Chuang CY, Chen CY.
    Lupus; 1997 May; 6(5):449-54. PubMed ID: 9229364
    [Abstract] [Full Text] [Related]

  • 12. Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus.
    Miyawaki Y, Sada K, Asano Y, Hayashi K, Yamamura Y, Hiramatsu S, Ohashi K, Morishita M, Watanabe H, Matsumoto Y, Kawabata T, Wada J.
    Lupus; 2018 Nov; 27(13):2093-2100. PubMed ID: 30309286
    [Abstract] [Full Text] [Related]

  • 13. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic.
    Nasiri S, Karimifar M, Bonakdar ZS, Salesi M.
    Rheumatol Int; 2010 Nov; 30(12):1605-9. PubMed ID: 19809816
    [Abstract] [Full Text] [Related]

  • 14. Anti-CII antibody as a novel indicator to assess disease activity in systemic lupus erythematosus.
    He C, Mao T, Feng Y, Song T, Qin C, Yan R, Feng P.
    Lupus; 2015 Nov; 24(13):1370-6. PubMed ID: 26048288
    [Abstract] [Full Text] [Related]

  • 15. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial.
    Tseng CE, Buyon JP, Kim M, Belmont HM, Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V, Abramson SB.
    Arthritis Rheum; 2006 Nov; 54(11):3623-32. PubMed ID: 17075807
    [Abstract] [Full Text] [Related]

  • 16. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy.
    Sakthiswary R, Suresh E.
    Lupus; 2014 Mar; 23(3):225-35. PubMed ID: 24399812
    [Abstract] [Full Text] [Related]

  • 17. Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity.
    Kim AHJ, Strand V, Sen DP, Fu Q, Mathis NL, Schmidt MJ, Bruchas RR, Staten NR, Olson PK, Stiening CM, Atkinson JP.
    Arthritis Rheumatol; 2019 Mar; 71(3):420-430. PubMed ID: 30294950
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of methotrexate in articular and cutaneous manifestations of systemic lupus erythematosus.
    Islam MN, Hossain M, Haq SA, Alam MN, Ten Klooster PM, Rasker JJ.
    Int J Rheum Dis; 2012 Feb; 15(1):62-8. PubMed ID: 22324948
    [Abstract] [Full Text] [Related]

  • 19. Correlation between clinical activity and serological markers in a wide cohort of patients with systemic lupus erythematosus: an eight-year prospective study.
    Villegas-Zambrano N, Martínez-Taboada VM, Bolívar A, San Martín M, Alvarez L, Marín MJ, López-Hoyos M.
    Ann N Y Acad Sci; 2009 Sep; 1173():60-6. PubMed ID: 19758133
    [Abstract] [Full Text] [Related]

  • 20. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus.
    Ho A, Barr SG, Magder LS, Petri M.
    Arthritis Rheum; 2001 Oct; 44(10):2350-7. PubMed ID: 11665976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.